Wearable Tech: Skin Tone Bias Persists in 2026

The promise of wearable tech for health tracking is immense, offering real-time insights into our bodies. However, a significant challenge persists: skin tone bias, which can compromise health tracking accuracy for a substantial portion of the global population. This issue isn’t just an inconvenience. It can lead to misdiagnoses or delayed interventions for individuals with darker skin tones, creating a stark disparity in care.

Consider the experience of Dr. Anya Sharma, a dermatologist practicing in Atlanta, Georgia. For years, she’d been an early adopter of health technology, incorporating various smartwatches and fitness trackers into her routine. Her interest wasn’t just personal. She saw the potential for these devices to help her patients in managing their skin conditions, from monitoring sun exposure to tracking hydration. Yet, she started noticing a pattern among her patients of color. “My lighter-skinned patients would rave about their sleep tracking or heart rate consistency,” Dr. Sharma explained during a recent Georgia Medical Association conference, “but my patients with richer complexions frequently reported discrepancies. Their devices would drop heart rate readings during exercise or give inconsistent SpO2 levels.”

This wasn’t an isolated observation. Dr. Sharma recalled a specific case in early 2024 involving a patient, Mr. David Chen, who presented with symptoms of chronic fatigue and occasional shortness of breath. His smartwatch, a popular model from a well-known tech firm, consistently reported normal blood oxygen levels. However, Dr. Sharma’s in-office pulse oximeter showed readings several points lower, prompting further investigation that in the end revealed a mild respiratory condition. “If we had relied solely on his wearable data, his diagnosis could have been significantly delayed,” she asserted, pointing to the critical flaw in relying on devices with inherent biases.

The Science Behind the Discrepancy: Melanin and Optical Sensors

The core of the problem lies in how many wearable health trackers operate. Most widely available devices use photoplethysmography (PPG) sensors, which emit light (typically green LED) into the skin and measure the amount of light reflected back. Blood absorbs light differently depending on its oxygenation level, allowing the device to estimate heart rate and blood oxygen saturation (SpO2). The challenge, as documented by numerous studies, is that melanin, the pigment responsible for skin color, also absorbs light. In individuals with darker skin tones, higher concentrations of melanin can interfere with the light signals, leading to inaccurate readings.

A complete review published in the journal Sensors in late 2023 highlighted that this interference can cause PPG sensors to underestimate SpO2 levels or struggle to obtain consistent heart rate data, especially during periods of movement or lower perfusion. This isn’t a new revelation. The U.S. Food and Drug Administration (FDA) issued a safety communication in February 2022 specifically addressing the limitations of pulse oximeters in individuals with darker skin pigmentation, acknowledging that these devices can “overestimate blood oxygen levels” in such populations. While the FDA’s focus was primarily on clinical pulse oximeters, the underlying optical sensing principles are shared with many consumer wearables, extending the concern to everyday health tracking.

Dr. Sharma emphasized this point. “It’s a physics problem, fundamentally,” she stated. “The light absorption by melanin can attenuate the signal, making it harder for the sensor to differentiate between blood flow and pigment. This means the algorithms have less reliable data to work with, leading to less accurate outputs.” She often advises patients to be aware of these limitations and not to treat wearable data as definitive medical diagnostics, particularly if their skin tone is not adequately represented in device validation studies.

Industry Response and Technological Advancements

The tech industry is not entirely unaware of this issue. Major players are increasingly investing in research and development to address skin tone bias. One promising avenue involves the use of multi-wavelength sensors. Instead of relying on a single green LED, newer devices are incorporating red and infrared light, which penetrate deeper into the skin and are less absorbed by melanin. By combining data from different wavelengths, algorithms can better differentiate between melanin absorption and blood flow dynamics.

For example, a prominent wearable manufacturer, known for its extensive health features, announced in late 2025 a new generation of its optical heart rate sensor array. This updated system utilizes three distinct wavelengths of light and an improved photodetector, explicitly designed to enhance performance across a broader spectrum of skin tones. Their internal white paper, presented at the International Conference on Biomedical Engineering in Atlanta, detailed how their new calibration protocols involved a diverse test group of over 5,000 individuals, ensuring a more equitable dataset for algorithm training. This level of transparency and commitment to diverse testing is a positive step, though it remains to be seen how quickly these advancements will propagate across all consumer-grade devices.

Another area of focus is the development of more sophisticated algorithms. Machine learning models, trained on vast datasets encompassing diverse skin tones and physiological responses, are becoming increasingly adept at compensating for signal interference. These algorithms can learn to identify and filter out noise caused by melanin, improving the signal-to-noise ratio and, consequently, the accuracy of the readings. However, the quality of these algorithms is entirely dependent on the diversity and robustness of the training data. If the initial datasets are predominantly from individuals with lighter skin, the bias will simply be perpetuated, regardless of how advanced the algorithm is.

The Call for Standardized Validation and Transparency

Dr. Sharma believes that industry-wide standards for validation are critical. “We need to move beyond self-reported accuracy claims,” she argued. “There should be independent, third-party validation studies that explicitly report device performance across different Fitzpatrick skin types. This isn’t just about ethical considerations. It’s about public health.” The Fitzpatrick scale, a numerical classification schema for human skin color, is often used in dermatology to categorize skin types based on their response to ultraviolet light. Incorporating this scale into device testing would provide a clear, quantifiable measure of performance across diverse populations.

Currently, the regulatory field for consumer wearables is somewhat fragmented. While medical devices undergo rigorous testing, many consumer health trackers operate in a less regulated space, often making claims that fall short of medical-grade accuracy. The FDA’s stance on pulse oximeters suggests a growing recognition of these issues, and it is plausible that future regulations or guidelines might extend to other consumer wearable health features. Consumers, in the meantime, are left to navigate a market where performance metrics for diverse populations are often absent or difficult to find.

For individuals like Mr. Chen, understanding these limitations is paramount. After his diagnosis, Dr. Sharma spent considerable time explaining the nuances of wearable tech. “I told him, ‘Your device is a good trend tracker, but it’s not a diagnostic tool, especially if you have a darker skin tone where the technology has known limitations.’ He appreciated the honesty,” she recounted. This highlights an important responsibility for healthcare providers: to educate patients about the capabilities and limitations of the health tech they use.

Looking Ahead: Equitable Health Tracking for All

The journey toward truly equitable health tracking accuracy in wearable tech is ongoing. The industry’s increasing awareness and the development of multi-wavelength sensors and advanced algorithms are encouraging signs. However, the onus also falls on consumers and healthcare professionals to demand greater transparency and more rigorous testing. We need to see more clinical trials, like those conducted by researchers at Emory University Hospital in Atlanta, that specifically recruit participants from all skin tones to validate device performance. Without this commitment, the promise of personalized health insights from wearable tech will remain unevenly distributed.

The future of wearable tech must prioritize inclusivity. As these devices become more integrated into our daily lives and even into clinical pathways, ensuring their accuracy for everyone, regardless of their skin tone, is not just a technical challenge. It’s a fundamental requirement for ethical and effective healthcare. Dr. Sharma remains optimistic. “The technology is evolving rapidly. We just need to ensure that this evolution is guided by principles of equity and validated by strong, inclusive science.”

The path forward involves a collaborative effort between tech manufacturers, regulatory bodies, medical professionals, and consumers. Only then can we truly use the power of wearable tech to improve health outcomes for every individual.